Figures & data
Table 1 Selected Baseline Characteristics of the Eligible Cohort
Figure 1 Flowchart of the study cohort assembly.
![Figure 1 Flowchart of the study cohort assembly.](/cms/asset/bd4044ad-9b4f-4920-ae0c-cd9228970826/dcop_a_12163948_f0001_b.jpg)
Table 2 Follow-Up, Event Rates, and Risk of COPD Exacerbations Comparing Statins with Fibrates
Figure 2 Kaplan–Meier curves for the probability of free of COPD exacerbations within 180 days after the index date (A) Kaplan–Meier curves before matching. (B) Kaplan–Meier curves after hd-PS matchinga. aData were weighted by matching ratio in the hd-PS matching analysis.
![Figure 2 Kaplan–Meier curves for the probability of free of COPD exacerbations within 180 days after the index date (A) Kaplan–Meier curves before matching. (B) Kaplan–Meier curves after hd-PS matchinga. aData were weighted by matching ratio in the hd-PS matching analysis.](/cms/asset/b319eb8a-a4f2-4f5f-863a-b389cbbdf607/dcop_a_12163948_f0002_c.jpg)
Table 3 Risk of COPD Exacerbations Comparing Statins with Fibrates, by Maximum Follow-Up Duration and Follow-Up Scheme
Table 4 Risk of COPD Exacerbations Comparing Statins with Fibrates, by Type of Statins and Patient Characteristic